登录  |  注册  |  设为首页  |  加入收藏  |  联系我们  |  繁体版

您当前的位置: 首页>>English >>Research and Forecast on China Insulin Market, 2014-2018

Research and Forecast on China Insulin Market, 2014-2018

慧典市场研究报告网(www.hdcmr.com)

Research and Forecast on China Insulin Market, 2014-2018

  • 【报告编号】: 610909
  • 【最新修订】: 2014年04月15日
  • 【关 键 字】: Insulin Market
  • 【报告页数】: 65
  • 【报告格式】: 电子版或纸介版
  • 【交付方式】: Email发送或EMS快递
  • 【价    格】: 纸介版:$2000    电子版:$1800
  • 【订购热线】: 010-51263229    010-51265563
报告导读:

报告目录

查看全部>>

Research and Forecast on China Insulin Market, 2014-2018

1. Overview of Insulin
1.1 Brief Introduction to Diabetes & General Situation of Related Therapeutic Drugs
1.1.1 Overview of Diabetes 
1.1.2 Clinical Classification of Diabetes
1.1.3 Major Therapeutic Drugs, Clinical Effects and Treatment Strategy 
1.2 Definition and Classification of Insulin
1.2.1 Definition 
1.2.2 Classification 
1.3 Development History of Insulin in China
1.3.1 First-Generation Insulin (Multi-component Insulin Extracted from Animal Pancreas)
1.3.2 Second-Generation Insulin (Insulin Human)
1.3.3 Third-Generation Insulin (Improved Insulin or Insulin Analogues)

2. Operation Environment of China Insulin Market in 2013
2.1 China’s Economic Environment in 2013
2.2 Policy Environment in 2013 
2.2.1 Opinions Concerning Deepening Medical and Health System Reform
2.2.2 Planning and Implementation of Deepening Medical and Health System Reform During the 12th Five-Year Plan
2.2.3 Comprehensive Improved Standards for Insulin and Recombinant Human Insulin in Chinese Pharmacopoeia 2010
2.2.4 Educational Management Standards for Using Insulin
2.2.5 Prevention Guideline of Type 2 Diabetes Mellitus in 2013
2.2.6 Continuous Anti-corruption in Medicine
2.3 Technological Environment in 2013 
2.3.1 Insulin Pump
2.3.2 Diabetes Treatment by Using Stem Cell Transplantation is on Clinical Test Stage
2.4 Chinese Consumers’ Cognition toward Insulin 

3. Trend of China Insulin Market in 2013
3.1 Present Situation 
3.1.1 Development Status of Diabetes in China and at Overseas
3.1.2 Market Scale 
3.2 New Pattern of China Insulin Industry in 2013

4. Import and Export Data of Product Segments of Insulin in China, 2011-2013 
4.1 Import and Export Data of Insulin and Its Salt in China, 2011-2013 (HS Code: 293712)
4.2 Export Data of Drugs Containing Insulin without Defined Daily Doses, 2011-2013 (HS Code: 300331)
4.3 Import and Export Data of Drugs Containing Insulin with Defined Daily Doses, 2011-2013 (HS Code: 300431)

5. Key Enterprises in Insulin Industry
5.1 Tonghua Dongbao 
5.1.1 Company Profile
5.1.2 Business Performance
5.1.3 Main Business Composition
5.1.4 Progress of Research and Development
5.1.5 Channel Expansion
5.1.6 Development Plan in 2014
5.2 Wanbang Biopharmaceuticals 
5.2.1 Company Profile
5.2.2 Business Performance
5.2.3 Third-Generation Insulin Approved to be used in Clinical Test
5.2.4 Marketing Network
5.2.5 Growth Pattern in the Next Five Years
5.3 United Laboratories 
5.3.1 Company Profile
5.3.2 Business Performance
5.3.3 Production Capacity
5.3.4 New Products
5.3.5 Marketing Promotion Channel 
5.3.6 Future Development Strategy 
5.4 Gan & Lee 
5.4.1 Company Profile
5.4.2 Business Performance
5.4.3 Commercial Bribery Case
5.4.4 Business Channel Expands to County-level Central Hospitals
5.5 Yabao Pharmaceutical Group 
5.5.1 Company Profile
5.5.2 Channel Building
5.5.3 Research & Development
5.6 Novo Nordisk 
5.6.1 Company Profile
5.6.2 Business Performance
5.6.3 Enterprise R&D
5.7 Eli Lilly and Company
5.7.1 Company Profile
5.7.2 Progress of R&D
5.7.3 Overall Increase of Insulin Production Capacity in China
5.7.4 Business Condition
5.7.5 Channel Expansion
5.8 SANOFI 
5.8.1 Company Profile
5.8.2 R&D Framework
5.8.3 Enterprise Operation

6. Development Trend and Prospect Forecast of China Insulin Market, 2014-2018
6.1 Development Prospect
6.1.1 Enormous Insulin Market Potential
6.1.2 Huge Oral Insulin Market Potential 
6.2 Development Trend 
6.2.1 Opportunities and Challenges for Enterprise R&D brought by Policy Environment Change
6.2.2 Development Trend of Insulin Products
6.3 China Insulin Market Forecast from 2014 to 2018 

报告描述

查看全部>>
Research and Forecast on China Insulin Market, 2014-2018 carries on a thorough analysis of development history, policy environment, import and export, new products and key enterprises of China Insulin Market. 

A survey conducted by Huidian Research shows that China’s insulin market scale approximately registered CNY 11 billion in 2013, of which CNY 7.5 billion achieved in second-generation insulin market and CNY 3.5 billion generated in third-generation insulin market. Now third-generation insulin market grows faster than second-generation insulin. And second-generation insulin market will accelerate growing space because it is just listed into new essential drug catalogue. 

Currently there are only two companies owning full series of insulin products globally, Tonghua Dongbao is one of the two. As for global insulin market at present, only three companies, including Tonghua Dongbao, Novo Nordisk and Eli Lilly, produce second-generation insulin in quantity. Under oligopolistic competition in the global market, it is difficult to tell which companies’ products are better, but Tonghua Dongbao enjoys the lowest overall production cost. Compared with expensive insulin produced by transnational giants, governments can reduce expenditure of health insurance if buying Dongbao’s insulin, so Tonghua Dongbao will become a powerful contender when competing for more market shares with transnational giants in the developing countries. 

Four domestic companies obtained production approval of second-generation insulin, namely United Laboratories, Donghua Tongbao, Wanbang and Shenzhen Kexing Biotech. The latter two received production approval in 2003, but their products did not sell in market due to bad quality. Currently Wanbang’s animal insulin injections enjoy the largest sales volume in China. 

Third-generation insulin in foreign market covers rapid-acting insulin (insulin aspart and insulin lispro) and long-acting insulin (insulin glargine and insulin detemir). Recombinant insulin lispro and its injection, which are high-end products, also belong to third-generation insulin. Third-generation insulin is quicker to take effects and also can better simulate physiologic insulin secretion pattern. Information disclosed by China Food and Drug Administration show that Eli Lilly and Company and Gan & Lee (a private company in China) owns production approval documents of this type of insulin. Affected by its commercial bribery case, business performance of Gan & Lee witnessed a significant drop in 2013, but its third-generation insulin that is a foreign-funded brand with dominant position in market had not been influenced much. 

Huidian Research holds a view that for now third-generation insulin is superior in effects but its price is far higher than second-generation insulin, so low and middle income patients without medical insurance are hard to pay for the expensive drug cost. So in wide grass roots market, second-generation insulin enjoys an overwhelming superiority. But it is predicated that with the decreasing price, third-generation insulin will replace second-generation insulin in the next years, representing the general trend. 

相关研究报告

报告搜索

  • 研究报告
  • 免费报告

购买流程

1.选择报告

① 按行业浏览 点击研究首页左边的行业分类 ② 按名称查询 输入关键字进行站内搜索

2.订购方式

① 电话购买:010-51263229 010-51265563 ② 在线订购 点击您需求的报告在线订购系统,在您注册填写正确的联系资料后,我们的服务人员会在24小时以内与您取得联系。 ③ 邮件定购 发送邮件到:

3.购买流程

  • (1)确定购买意向电话或网络确定购买细节
  • (2)签订服务合同签订研究报告购买合同
  • (3)签订服务合同支付报告购买款项
  • (4)购买成功支付报告并售后服务一年

4.汇款信息

开户名:北京市北福源信息咨询有限公司 帐 号:35090188000014650 开户行:光大银行亚运村支行

手机扫描二维码区域

版权所有:慧典市场研究报告网

电话:(86)010-51265563 010-51263229 传真:010-84985706   客服邮件:

京ICP备05012231号-1